Press Release – Holbæk, 6 October 2025

Pharmacosmos breaks ground on major expansion

Pharmacosmos today marked the beginning of a significant expansion of its headquarters in Holbæk. The project will add 5,200 m² of modern laboratories, offices, and shared facilities and as part of a larger investment program of approximately DKK 300 million. The program also includes upgrading selected parts of existing production equipment and a new 1,400 m² warehouse. The expansion will ensure that Pharmacosmos can meet growing demand and create the framework for continued growth.

In recent years, Pharmacosmos has undergone significant development. Revenue has quadrupled since 2020, and with the acquisition and integration of the US company G1 Therapeutics, Inc., Pharmacosmos has strengthened its foundation for continued global growth. As a result, the number of employees at the Holbæk headquarters has grown by 20% in just one year, and recruitment needs are expected to continue.

Pharmacosmos is in a historic phase of development. Our products and the research that supports them, our talented employees, and our ability to integrate new product areas create a strong foundation for the future. With this expansion, we are not only investing in bricks and mortar but also in our employees, our production, and our continued ambition to be a leading international company in the treatment of blood diseases.''

Tobias S. Christensen continues:

We wanted to create facilities that give our employees in Holbæk the best possible working environment with modern facilities, light, and space, in harmony with the rest of the building and surroundings. I would also like to thank Holbæk Municipality for the support and cooperation we have received throughout the process.''

The Mayor of Holbæk, Christina Krzyrosiak Hansen, participated in the ceremony and highlighted the importance for the municipality:

Pharmacosmos is one of the real beacons of Holbæk’s business community, and I am proud that the company, with its presence in Holbæk, has both celebrated its 60th anniversary and is at the same time investing heavily in the future. The expansion is a strong signal of growth, innovation, and jobs, and it strengthens both the municipality and the business environment in Northwest Zealand. With its commitment, Pharmacosmos demonstrates that a company can be locally rooted while maintaining a global outlook, to the great benefit of both employees and the local business community.''

Facts about the construction

• Extension of 5,200 m² with new offices, laboratories, reception, and canteen.

• In addition, a new 1,400 m² warehouse building and upgrading of existing equipment.

• Architect for the extension: Christensen & Co Architects.

• Contractor for the extension: C.C. Contractor A/S.

• Timeline: Expected completion mid-2027.

• Total investment: approx. DKK 300 million.

About Pharmacosmos

Pharmacosmos A/S is a global leader in carbohydrate chemistry and innovative treatments for iron deficiency and iron deficiency anaemia. Building on our foundational expertise in carbohydrate chemistry and cell cycle biology, we develop innovative treatments for unmet patient needs, with a focus on iron metabolism and blood-related disorders. Founded in 1965 and headquartered in Denmark, our team is made up of more than 700 specialists across the UK, Ireland, the Nordics, Germany, the USA, and China.

For more information, please contact:

Christian Lundquist Madsen,

Vice President, Global Marketing & Communication

+45 5948 5959, clm@pharmacosmos.com